Clinical trials: Medication Assisted Treatment
Breast Cancer, Peripheral Neuropathy, Secondary to Drugs or Chemicals
Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
The cause of Chemotherapy-Induced Peripheral Neuropathy (CIPN) is still unknown. An estimated 55-60% of patients will experience lasting symptoms affecting function for years post-treatment.
- Trial name
- NCT02239601
- Testing
- Physical Therapy
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- CancerCare Manitoba
Opioid-use Disorder
Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)
Project STAMINA is a clinical trial that seeks to establish effectiveness of a telemedicine approach for linking syringe exchange clients to medications for opioid use disorder.
- Trial name
- STAMINA (NCT04575324)
- Testing
- Telemedicine Linkage Intervention
- Where
- United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Chestnut Health Systems
Opioid-use Disorder, Mental Disorder
Start Treatment and Recovery for Opioid Use Disorder
The purpose of this study is 1) to evaluate whether emergency department-initiated medically assisted treatment with Buprenorphine/Naloxone in patients presenting with opioid use disorder will produce positive outcomes at 1 week…
- Conditions
- Opioid-use Disorder, Mental Disorder, Opioid Medication Assisted Treatment
- Trial name
- STAR (NCT04505540)
- Testing
- Bridge Clinic
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Vermont
Opioid-use Disorder, Medication Assisted Treatment
Minds and Mentors Program (MiMP)- R61
The proposed research effort will: The purpose of this study is as follows: 1. Test the feasibility and acceptability of a twelve- week mindfulness based relapse prevention protocol in combination with peer mentoring in…
- Conditions
- Opioid-use Disorder, Medication Assisted Treatment, Substance Use Disorders
- Trial name
- MiMP (NCT04233671)
- Testing
- Mindfulness based relapse prevention and peer mentoring
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Alabama, Tuscaloosa
Smoking Cessation
Novel Smoking Cessation Drug for Schizophrenia
The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest in quitting.
- Trial name
- TRENDS (NCT02230384)
- Testing
- Active JNJ Drug
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- K.N. Roy Chengappa
Heart Failure, Dilated Cardiomyopathy
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover…
- Trial name
- HARPS (NCT00585546)
- Testing
- clenbuterol
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Francis D. Pagani
Opioid-use Disorder
Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
The primary objective of this pilot study is to program an opioid use disorder (OUD) clinical decision support (CDS) tool for use in an electronic medical record (EMR) and obtain high primary care physician (PCP) usability and…
- Trial name
- COMPUTE (NCT03559179)
- Testing
- Opioid Wizard
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Alcohol Use Disorder
ED Initiated Oral Naltrexone for AUD
This study will recruit Emergency Department (ED) patients with moderate to severe alcohol use disorder (AUD) who are interested in initiating medication assisted treatment (MAT). The study is split into two phases.
- Trial name
- NCT04817410
- Testing
- Emergency Department Initiated Oral Naltrexone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pancreatic Ductal Adenocarcinoma, Pain, Acute
Ketamine-assisted Therapy for Advanced GI Cancer
This clinical trial evaluates whether it is possible to use a single dose of ketamine in combination with talk therapy to treat moderate to severe demoralization in patients with stage 3 or 4 gastrointestinal (GI) cancers who…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
- Trial name
- NCT06077487
- Testing
- Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Brian Anderson, MD
Opioid-use Disorder
reSET-O RCT (Randomized Controlled Trial)
This randomized controlled trial research study will be evaluating an app, reSET-O, owned by Pear Therapeutics, Inc., to evaluate treatment retention rates in individuals with opioid use disorder after initiating medication…
- Trial name
- NCT04129580
- Testing
- reSET-O app
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Milton S. Hershey Medical Center
Post-operative Situation
Study of a Prototype Software to Help Surgical Patients Manage Their Pain Medication
The experimental medical device is a prototype software. The device comes in the form of a smartphone with a touch interface. The smartphone used to support the software is a commercial smartphone marked CE.
- Trial name
- MORPHEE 2 (NCT05707247)
- Testing
- software
- Where
- France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Pain
Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
The purpose of this study is to determine the effectiveness and safety of single intravenous doses of the kappa opioid agonist CR845 in relieving pain in patients following laparoscopic-assisted hysterectomy surgery.
- Trial name
- NCT00877799
- Testing
- CR845
- Where
- 12 sites in United States
- Volunteers
- 114 people
- Sponsor
- Cara Therapeutics, Inc.
Tuberculosis, Drug-resistant Tuberculosis
An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
This study is a U.S.-based, 1 site (with 4 clinical settings), randomized controlled trial (with funding from the Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Solutions Initiative) that will be…
- Conditions
- Tuberculosis, Drug-resistant Tuberculosis, Adherence, Medication, Adherence, Patient
- Trial name
- NCT03266003
- Testing
- Electronic DOT, In-person DOT
- Where
- 4 sites in United States
- Volunteers
- 216 people
- Sponsor
- Centers for Disease Control and Prevention
Contraception
Improving Reproductive Health for Women in Opioid Medication-Assisted Treatment (OMAT)
Recent research suggests that women with substance use disorders may be at a higher risk of unintended pregnancy. There is a paucity of interventions specifically focused on this population.
- Trial name
- NCT02794597
- Testing
- SHINE intervention group
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Opioid-use Disorder, Contingency Management
Usability Testing for the Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden.
- Conditions
- Opioid-use Disorder, Contingency Management, Medication for Opioid-use Disorder
- Trial name
- OARSCM (NCT05159362)
- Testing
- Software Application
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder
Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common…
- Trial name
- OARSCM (NCT05180669)
- Testing
- OARSCM Software Application, MyMAT Software Application
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Q2i, LLC
Heart Failure, Medication Compliance
Monitoring Medication Adherence in Left Ventricular Assist Device Recipients
The investigators aim to develop a novel and wireless method for monitoring medication adherence among heart failure patients with left ventricular assist devices (LVADs).
- Trial name
- NCT02388386
- Testing
- PROTEUS-SENSOR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Scripps Translational Science Institute
Opioid-use Disorder
Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
This proposal aims to determine whether an adjunctive Mindfulness-Based Relapse Prevention (MBRP) treatment program improves Medication Assisted Treatment (MAT) adherence and reduces drug-use among opioid use disorder (OUD)…
- Trial name
- NCT05042388
- Testing
- Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA), Treatment-As-Usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- West Chester University of Pennsylvania
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania